CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company developing bladder-sparing therapeutics for bladder cancer, has announced upcoming presentations at two major investor conferences. The company's leadership team, including Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete, will participate in fireside chats at:

- The Cantor Global Healthcare Conference on September 5, 2025, at 10:20am ET
- The Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45am ET

Both presentations will be accessible via webcast on the company's investor relations website and will remain archived for approximately 90 days.

News Market Reaction

+0.39%

1 alert

+0.39% News Effect

+$8M Valuation Impact

$2.04B Market Cap

2K Volume

On the day this news was published, CGON gained 0.39%, reflecting a mild positive market reaction. This price movement added approximately $8M to the company's valuation, bringing the market cap to $2.04B at that time.

Data tracked by StockTitan Argus on the day of publication.

IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:

• Cantor Global Healthcare Conference – presenting Friday, September 5, 2025, at 10:20am ET in New York, NY
• Morgan Stanley 23rd Annual Global Healthcare Conference – presenting Tuesday, September 9, 2025, at 7:45am ET in New York, NY
  
  

Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com

FAQ

When is CG Oncology (CGON) presenting at the Cantor Global Healthcare Conference 2025?

CG Oncology will present at the Cantor Global Healthcare Conference on Friday, September 5, 2025, at 10:20am ET in New York, NY.

When is CG Oncology's presentation at the Morgan Stanley Healthcare Conference 2025?

CG Oncology will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 9, 2025, at 7:45am ET in New York, NY.

How can investors access CG Oncology's (CGON) conference presentations?

Investors can access the live audio webcasts through the Investor Relations section of CG Oncology's website at www.cgoncology.com. Replays will be available for approximately 90 days after the presentations.

What type of company is CG Oncology (CGON)?

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutic solutions for patients with bladder cancer.